SCHEMBL43914

SCHEMBL43914

NC(Cc1ccc(Cl)c(Cl)c1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.62
PTGS1 P23219 3/20 0.62
ALOX15 P16050 3/20 0.62
HIF1A Q16665 3/20 0.62
KDM4E B2RXH2 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
USP2 O75604 1/20 0.62
EGFR P00533 1/20 0.62
LCK P06239 1/20 0.62
FYN P06241 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
HTR2A P28223 1/20 0.62
PTGS2 P35354 1/20 0.62
RECQL P46063 1/20 0.62
HSD17B10 Q99714 1/20 0.62
PNMT P11086 1/20 0.58
KMO O15229 2/20 0.57
PKM P14618 2/20 0.56
ALPI P09923 1/20 0.56
XIAP P98170 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397861 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29478421 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL43915 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL289165 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29778 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL157442 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL28512 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL1093972 0.86 SLC7A5 (0.58) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29405778 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL1093973 0.86 SLC7A5 (0.58) SLC7A5PTGS1ALOX15HIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1942 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-11-06 US claimed
US-20250304620-A1 ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2025-10-02 US claimed
US-12428447-B2 Peptide-based non-proteinaceous cargo delivery FELDAN BIO INC. (CA) 2025-09-30 US claimed
EP-4448544-A2 CARBONIC ANHYDRASE IX LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-10-23 EP claimed
EP-4401555-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-07-24 EP claimed
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY FELDAN BIO INC. (CA) 2024-06-20 US claimed
CN-117466974-B Antimicrobial peptide and application thereof 中国药科大学 2024-03-26 CN claimed
CN-117750978-A Synthetic peptide shuttle bioconjugates for intracellular cargo delivery 费尔丹生物公司 2024-03-22 CN claimed
EP-4313159-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY Feldan Bio Inc. (CA) 2024-02-07 EP claimed
CN-117466974-A Antimicrobial peptide and application thereof 中国药科大学 2024-01-30 CN claimed
WO-2002067994-A2 COMPOUNDS COMPRISING AN ANALGESIC MOLECULE LINKED TO A VECTOR THAT CAN VECTORISE SAID MOLECULE THROUGH THE HEMATOENCEPHALIC BARRIER AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SYNT:EM (FR) 2002-09-06 WO claimed
US-6232305-B1 ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS NAEJA PHARMACEUTICAL INC. (CA) 2001-05-15 US claimed
EP-1003771-A1 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES Synt:em (S.A.) (FR) 2000-05-31 EP claimed
EP-0646596-B1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1999-05-26 EP claimed
WO-1999007728-A2 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES SYNT:EM (S.A.) (FR) 1999-02-18 WO claimed
EP-0646595-B1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1998-11-04 EP claimed
US-5623049-A FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS BAYER AKTIENGESELLSCHAFT (DE) 1997-04-22 US claimed
EP-0700928-A1 Nucleic acid-binding oligomers for therapy and diagnostics BAYER AG (DE) 1996-03-13 EP claimed
EP-0646595-A1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1995-04-05 EP claimed
EP-0646596-A1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1995-04-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY SCAMP2, SLC7A1, NUMA1 SLC7A5 35/4885PTGS1 4470/4885ALOX15 4632/4885
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS CA9, CA13, CA4 SLC7A5 780/4885PTGS1 3908/4885ALOX15 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.